Prescient Therapeutics Limited (ASX:PTX)
Australia · Delayed Price · Currency is AUD 0.0490
-0.0010 (-2.00%)
Oct 29, 2025, 3:44 PM AEST
Prescient Therapeutics Company Description
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia.
Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1.
The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014.
Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Prescient Therapeutics Limited
| Country | Australia |
| Founded | 1986 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | James McDonnell |
Contact Details
Address: Suite 2 Melbourne, 3000 Australia | |
| Phone | 61 3 9692 7222 |
| Website | ptxtherapeutics.com |
Stock Details
| Ticker Symbol | PTX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000PTX3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| James McDonnell | Chief Executive Officer |
| Melanie Jaye Leydin B.Bus, C.A., CA | Chief Financial Officer and Company Secretary |
| Dr. Rebecca Tunstall | Chief Operating Officer |
| Dr. Marissa Lim M.B.A., MBBS | Chief Medical Officer |